Bioanalytical Services

Q2 Solutions understands that bringing a promising drug candidate to market requires a well-planned strategy that incorporates sensitive, specific, and validated assays to inform development decisions. As such, our highly trained scientists apply leading-edge technologies, automated platforms, and state-of-the-art techniques to support a wide range of bioanalytical services and ADME services.


From high-throughput ADME screening services and human clearance predictions to support drug metabolism and pharmacokinetics studies to drug-drug interaction testing and metabolite profiling to support clinical safety, the Q2 Solutions global network offers solutions to support every phase of drug discovery and development.


Our bioanalysis services include:

  • In vitro ADME screening assays and discovery and development metabolite identification services that enable rapid drug discovery ADME property optimization and regulatory filings
  • Bioanalytical liquid chromatography mass spectrometry services for the quantitative determination of small molecule drugs and macromolecule therapeutics to support pharmacokinetic (PK) testing
  • Immunoassay services, including ELISA, MSD, ECL, and neutralizing antibody assays to facilitate pharmacokinetic (PK) testing and immunogenicity testing
  • Biomarker assays using LC/MS analysis and ligand-binding assays to quantitate biomarkers in biologic matrices.


In addition to specific services detailed in the sections below, Q2 Solutions can provide bundled services for discovery and regulatory-phase packages to enable decision-making at each step of the development process.

Our integrated drug metabolism solutions include high-throughput screening assays, human clearance predictions, drug-drug interaction risk assessments and metabolite profiling to support clinical safety.

Related Thought Leaders Insights

Choosing HRMS vs LBA for Bioanalysis

There is an increase in the complexity of drug modalities along with the need for more sensitive methods. Immunoassays, while often chosen as the first platform to utilize for assessing...

A collaborative translational informatics environment at the NCI

Translational research programs have been created to provide a better understanding of disease susceptibilities and pathway mechanisms. These programs require integration and analysis of multiple...

Merck BBMS: A clinical trials specimen management system

Learn more about Merck’s Biospecimen and Biorepository Management System (BBMS) - a transformational informatics project that improves operational visibility, increases efficiency, and maintains...